REGISTERED COMPANY NUMBER: CE018092 (England and Wales) REGISTERED CHARITY NUMBER: 231708
Report of the Trustees and
Financial Statements for the Year Ended 31 October 2022
for
The Thalidomide Society
Lewis Smith & Co. Chartered Certified Accountants The Old Doctor's House 74 Grange Road Dudley West Midlands DY1 2AW
The Thalidomide Society
Contents of the Financial Statements for the Year Ended 31 October 2022
| Page | |||
|---|---|---|---|
| Reference and Administrative Details | 1 | ||
| Report of the Trustees | 2 | to | 4 |
| Independent Examiner's Report | 5 | ||
| Statement of Financial Activities | 6 | ||
| Balance Sheet | 7 | ||
| Notes to the Financial Statements | 8 | to | 13 |
| Detailed Statement of Financial Activities | 14 | to | 15 |
The Thalidomide Society Reference and Administrative Details for the Year Ended 31 October 2022
| TRUSTEES | Mr G Spink (resigned 31.5.22) |
|---|---|
| Ms K West | |
| Mr D Mansell | |
| Mr G Tweedy | |
| Ms M Hogg | |
| Ms G Freeman | |
| Mr R Bareham | |
| Ms M De La Mare | |
| Mr B Payne (resigned 31.5.22) | |
| Ms S Thakkar | |
| Ms M Argy (appointed 16.6.22) | |
| Mr D Tickell (appointed 1.9.22) | |
| REGISTERED OFFICE | Flat 29 Weymouth House |
| Hill House Mews | |
| Bromley | |
| BR2 0DD | |
| REGISTERED COMPANY | CE018092 (England and Wales) |
| NUMBER | |
| REGISTERED CHARITY | 231708 |
| NUMBER | |
| INDEPENDENT EXAMINER | Lewis Smith & Co. |
| Chartered Certified Accountants | |
| The Old Doctor's House | |
| 74 Grange Road | |
| Dudley | |
| West Midlands | |
| DY1 2AW |
Page 1
The Thalidomide Society
Report of the Trustees for the Year Ended 31 October 2022
The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 October 2022. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).
OBJECTIVES AND ACTIVITIES
General Overview
The Board of Trustees meets four times a year (usually in October, February, March and June) to discuss the work of the Society, to review investments and to plan ahead. These meetings mostly now take place on Zoom but as an event draws near they are more likely to be in person. In between meetings the trustees communicate by email and Zoom, to discuss matters arising and to move forward on all outstanding issues as they arise.
The Board has three subcommittees: Finance, Governance and Events. The Finance and Governance subcommittees meet at least once a year and the Governance, Events and Communications as and when necessary.
The Society has a website to share information about the activities of the Society with the public and its members. The Society also has a Facebook page and Twitter account through which information is shared with members. The Society produces a yearly newsletter which is sent to all members and holds an Annual General Meeting and conference to which all members are invited.
2022 60th celebration
The Board of Trustees celebrated 60 years of the Society by holding a big event at the Marriott Hotel, Heathrow. This took a lot of thought and planning leading up to the event and frequent extra event meetings.
Highlights included a talk from the team from Call the Midwife, an address from Baroness Jane Campbell, Mat Fraser as host, presentations from the Science Museum, Neil Vargesson, Stephen Simmonds on the Thalidomide Memorial and a moving 'role call' in which fellow thalidomiders who are no longer living were remembered.
There was also a continuous film screening of some of the Society's films and other films which were considered of most importance and relevance by the Board. Rockitfish provided AV support and entertainment as well as hosting the online attendees who came from across the world. There was a craft stall with donations from the wider thalidomide community, a raffle with some unique prizes and a lot of time was spent ensuring that the room and decorations looked special.
2022 Annual General Meeting
The AGM was held separately to the conference this year because the 60th celebrations were so extensive and time consuming that the Board and staff were too exhausted to hold it the same weekend. We completed all of the necessary paperwork and submissions to the Charity Commission and all members remained notified and were able to vote as usual.
The Board of Trustees
The Board of Trustees welcomed Mikey Argy and David Tickell as new trustees. Brian Payne and Geoff Spink resigned from the Board. Kath West was voted in as chair and Darren Mansell as vice chair. Mandy de la Mare was voted in as line manager to the secretary. Darren Mansell was voted chair of finance, Mikey Argy was voted chair of governance and Geraldine Freeman was voted chair of events.
Progress is almost complete on the HLF-funded oral history project, Thalidomide Stories, which sees nine thalidomide survivors trained as oral historians, undertaking oral history interviews with fellow survivors. Forty-nine interviews are now completed in full with transcripts and interview summaries in accordance with British Library guidelines. One of the project aims was to build our outreach activities to thalidomide survivors who do not usually attend Society events or may never have met any other survivors. This has been very successful. The Parents' Oral History Project has had no new interviews.
Progress has also been made on the Society's historical archiving; all of the early Board meeting documents and minutes as well as early information bulletins and leaflets have been completed.
Former trustee Marie Pearse has continued to run the successful Lottery Project.
Page 2
The Thalidomide Society
Report of the Trustees for the Year Ended 31 October 2022
ACHIEVEMENT AND PERFORMANCE
Investment Policy and Performance
At the year end the balance of the Society's investment portfolio was valued at £513,337 (2021 - £581,895) and generated income during the year of £22,125 (2021 - £19,086). The value of the investment portfolio significantly reduced because of market performance and disinvestments during the year for cashflow purposes. The Finance Committee actively monitors these investments.
FINANCIAL REVIEW
Financial position
Total income for the year was £90,437 (2021 - £22,376). Expenditure for the year (excluding the investment movements) was £132,862 (2021 - £59,817). The total funds of the charity increased to £551,210 (2021 - £621,177). This consisted of unrestricted funds of £529,419 (2021 - £598,092) and restricted funds of £21,791 (2021 - £23,085).
Restricted Funds
The restricted funds are accounted for separately. These funds are generated from several sources and are restricted for specific projects. These are:
Support for Srey Hang
Funds are generated from the Society's raffle and auctions at the AGM, as well as from occasional separate private donations and bequests. This money has now all been sent to Srey Hang.
Oral History Project: Thalidomide Stories
In July 2018 the Society was granted £96,935 of Heritage Lottery funding for Thalidomide Stories: An Oral History of Thalidomide Survivors. The funds will be used solely for this project. So far funding of £88,740 has been received of which £82,464 has been spent on delivery of the project.
Oral History Project: Parents' Oral History
Funds generated from private bequests, net receipts from the Thalidomide Society Lottery, specific gifts from members and donations are used to support the Society's Parents' Oral History Project. Occasionally funds here too may be used to fund an interview with a thalidomide survivor or someone involved in the thalidomide community when it is needed for a specific talk or presentation on behalf of the Society.
Unrestricted Funds
The Society generates most of its unrestricted funds from its investment portfolio and uses this income to cover charitable activities and governance costs.
Reserves policy
Apart from the Restricted Funds, all reserves available for use by the Society are unrestricted and can be used for the Society in accordance with its charitable aims. The Trustees are aware the Society depends upon the income from its investments to fund its core activities and recognise the need to source other income to embark on any major projects.
FUTURE DEVELOPMENT
The Society aims to continue with archival digitisation work to protect its heritage and enhance the website content which we are already making progress with. A book contract has been proposed by Polity Press through which the Society can produce a social history of thalidomide, using the words of survivors.
The HLF-funded oral history project will be a strong focus for the next year, with a presentation to members at the 2022 event. The Society will continue to support Srey Hang and continue too with gathering parent oral histories.
STRUCTURE, GOVERNANCE AND MANAGEMENT
Governing document
The charity is controlled by its governing document, a CIO Association conversion dated 4 July 2019.
Risk management
The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error.
Page 3
The Thalidomide Society
Report of the Trustees for the Year Ended 31 October 2022
TRUSTEES INFORMATION
The details of the charity's trustees can be found on the Reference and Administrative Details on page 1 of the accounts.
The following people are not trustees of the charity but hold the following positions:
| Name | Position |
|---|---|
| Dr R Blue | Secretary to the Board of Trustees |
| J Tunbridge | Honorary Treasurer |
| Approved by order of the board of trustees on ............................................. and signed on its behalf by: |
........................................................................ Mr D Mansell - Trustee
Page 4
Independent Examiner's Report to the Trustees of The Thalidomide Society
Independent examiner's report to the trustees of The Thalidomide Society ('the Company')
I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 October 2022.
Responsibilities and basis of report
As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').
Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.
Independent examiner's statement
I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:
-
accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
-
the accounts do not accord with those records; or
-
the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
-
the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).
I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.
Mr Craig Alan Beale
Lewis Smith & Co. Chartered Certified Accountants The Old Doctor's House 74 Grange Road Dudley West Midlands DY1 2AW Date: .............................................
Page 5
The Thalidomide Society
Statement of Financial Activities for the Year Ended 31 October 2022
| Unrestricted fund Notes £ INCOME AND ENDOWMENTS FROM Donations and legacies 36,588 Other trading activities 3 1,073 Investment income 4 22,117 Other income 23,107 Total 82,885 EXPENDITURE ON Charitable activities Staff costs 30,444 Other charges 93,572 Charitable activities - Total 124,016 Net gains/(losses) on investments (27,542) NET INCOME/(EXPENDITURE) (68,673) RECONCILIATION OF FUNDS Total funds brought forward 598,092 TOTAL FUNDS CARRIED FORWARD 529,419 |
Restricted funds £ 7,544 - 8 - 7,552 6,344 1,160 1,342 8,846 - (1,294) 23,085 21,791 |
31.10.22 31.10.21 Total Total funds funds £ £ 44,132 3,290 1,073 - 22,125 19,086 23,107 - 90,437 22,376 36,788 34,247 94,732 25,570 1,342 - 132,862 59,817 (27,542) 107,121 (69,967) 69,680 621,177 551,497 551,210 621,177 |
31.10.22 31.10.21 Total Total funds funds £ £ 44,132 3,290 1,073 - 22,125 19,086 23,107 - 90,437 22,376 36,788 34,247 94,732 25,570 1,342 - 132,862 59,817 (27,542) 107,121 (69,967) 69,680 621,177 551,497 551,210 621,177 |
|---|---|---|---|
| 22,376 | |||
| 34,247 25,570 - |
|||
| 59,817 | |||
| 107,121 | |||
| 69,680 551,497 |
|||
| 621,177 |
The notes form part of these financial statements
Page 6
The Thalidomide Society
Balance Sheet
31 October 2022
| Unrestricted fund Notes £ CURRENT ASSETS Debtors 8 1,183 Investments 9 513,337 Cash at bank 17,379 531,899 CREDITORS Amounts falling due within one year 10 (2,480) NET CURRENT ASSETS 529,419 TOTAL ASSETS LESS CURRENT LIABILITIES 529,419 NET ASSETS 529,419 FUNDS 11 Unrestricted funds Restricted funds TOTAL FUNDS |
Restricted funds £ - - 23,297 23,297 (1,506) 21,791 21,791 21,791 |
31.10.22 Total funds £ 1,183 513,337 40,676 555,196 (3,986) 551,210 551,210 551,210 529,419 21,791 551,210 |
31.10.21 Total funds £ 7,320 581,895 33,882 623,097 (1,920) 621,177 621,177 621,177 598,092 23,085 621,177 |
|---|---|---|---|
The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 October 2022.
The members have not required the company to obtain an audit of its financial statements for the year ended 31 October 2022 in accordance with Section 476 of the Companies Act 2006.
-
The trustees acknowledge their responsibilities for
-
(a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
-
(b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.
These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.
The financial statements were approved by the Board of Trustees and authorised for issue on ............................................. and were signed on its behalf by:
............................................. Mr D Mansell - Trustee
The notes form part of these financial statements
Page 7
The Thalidomide Society
Notes to the Financial Statements for the Year Ended 31 October 2022
1. GENERAL INFORMATION
The Thalidomide Society is a Charitable Incorporated Organisation (CIO). Its principal activity is to work with thalidomide and similarly impaired people, their families and supporters, providing a social network for thalidomide and similarly impaired people. Its registered office is Flat 29, Weymouth House, Hill House Mews, Bromley, BR2 0DD
Company Status
The charity is a Charitable Incorporated Organisation (CIO). It is registered on Companies House with the company number CE018092 but is not required to submit and accounts or other documents with them. The company is registered with The Charity Commission with the charity number the 231708. It is required to file an annual report with them which includes a copy of these accounts.
2. ACCOUNTING POLICIES
Basis of preparing the financial statements
The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.
Income
All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.
Expenditure
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.
Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.
Taxation
The charity is exempt from corporation tax on its charitable activities.
Fund accounting
Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.
Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.
Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.
Pension costs and other post-retirement benefits
The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.
Debtors
Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid.
continued...
Page 8
The Thalidomide Society Notes to the Financial Statements - continued for the Year Ended 31 October 2022
2. ACCOUNTING POLICIES - continued
Cash at bank and in hand
Cash at bank and in hand includes cash and short-term liquid investments with a short maturity of 3 months or less from the date of acquisition or opening of the deposit or similar account.
Liabilities
Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.
Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.
3. OTHER TRADING ACTIVITIES
4.
| OTHER TRADING ACTIVITIES | ||
|---|---|---|
| 31.10.22 | 31.10.21 | |
| £ | £ | |
| Merchandise income | 1,073 | - |
| INVESTMENT INCOME | ||
| 31.10.22 | 31.10.21 | |
| £ | £ | |
| Investment income | 22,125 | 19,086 |
5. TRUSTEES' REMUNERATION AND BENEFITS
There were no trustees' remuneration or other benefits for the year ended 31 October 2022 nor for the year ended 31 October 2021.
Trustees' expenses
There were no trustees' expenses paid for the year ended 31 October 2022 nor for the year ended 31 October 2021.
6. STAFF COSTS
| 31.10.22 | 31.10.21 | |
|---|---|---|
| £ | £ | |
| Wages and salaries | 31,817 | 27,607 |
| Social security costs | (323) | 3,922 |
| Other pension costs | 1,516 | 1,144 |
| 33,010 | 32,673 | |
| The average monthly number of employees during the year was as follows: | ||
| 31.10.22 | 31.10.21 | |
| Employees | 2 | 2 |
No employees received emoluments in excess of £60,000.
continued...
Page 9
The Thalidomide Society
Notes to the Financial Statements - continued for the Year Ended 31 October 2022
| 7. | COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES | COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES | ||
|---|---|---|---|---|
| Unrestricted | Restricted | Total | ||
| fund | funds | funds | ||
| £ | £ | £ | ||
| INCOME AND ENDOWMENTS FROM | ||||
| Donations and legacies | 789 | 2,501 | 3,290 | |
| Investment income | 19,074 | 12 | 19,086 | |
| Total | 19,863 | 2,513 | 22,376 | |
| EXPENDITURE ON | ||||
| Charitable activities | ||||
| Staff costs | 25,963 | 8,284 | 34,247 | |
| Other charges | 17,379 | 8,191 | 25,570 | |
| Total | 43,342 | 16,475 | 59,817 | |
| Net gains on investments | 107,121 | - | 107,121 | |
| NET INCOME/(EXPENDITURE) | 83,642 | (13,962) | 69,680 | |
| RECONCILIATION OF FUNDS | ||||
| Total funds brought forward | 514,450 | 37,047 | 551,497 | |
| TOTAL FUNDS CARRIED FORWARD | 598,092 | 23,085 | 621,177 | |
| 8. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR | |||
| 31.10.22 | 31.10.21 | |||
| £ | £ | |||
| PAYE & NI tax | 1,183 | - | ||
| Prepayments and accrued income | - | 7,320 | ||
| 1,183 | 7,320 | |||
| 9. | CURRENT ASSET INVESTMENTS | |||
| 31.10.22 | 31.10.21 | |||
| £ | £ | |||
| Listed investments | 513,337 | 581,895 |
continued...
Page 10
The Thalidomide Society
Notes to the Financial Statements - continued for the Year Ended 31 October 2022
10. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
| 31.10.22 | 31.10.21 | ||
|---|---|---|---|
| £ | £ | ||
| Pension creditor | 391 | - | |
| Accruals and deferred income | 3,595 | 1,920 | |
| 3,986 | 1,920 | ||
| 11. | MOVEMENT IN FUNDS |
| Unrestricted funds General fund Restricted funds Thalidomide Society Oral History Support for Srey Hang Srey Hang & Beyond HLF TOTAL FUNDS Net movement in funds, included in the above are a Unrestricted funds General fund Restricted funds Thalidomide Society Oral History Support for Srey Hang Srey Hang & Beyond HLF TOTAL FUNDS |
s follows: Incoming resources £ 82,885 7,546 - 2 4 7,552 90,437 |
At 1.11.21 £ 598,092 3,760 1,341 4,555 13,429 23,085 621,177 Resources expended £ (124,016) (408) (1,341) (1) (7,096) (8,846) (132,862) |
Net movement At in funds 31.10.22 £ £ (68,673) 529,419 7,138 10,898 (1,341) - 1 4,556 (7,092) 6,337 (1,294) 21,791 (69,967) 551,210 Gains and Movemen losses in funds £ £ (27,542) (68,673 - 7,138 - (1,341 - 1 - (7,092 - (1,294 (27,542) (69,967 |
At 31.10.22 £ 529,419 10,898 - 4,556 6,337 |
|---|---|---|---|---|
| 21,791 | ||||
| 551,210 | ||||
| (1,294 | ||||
| (69,967 |
continued...
Page 11
The Thalidomide Society
Notes to the Financial Statements - continued for the Year Ended 31 October 2022
11. MOVEMENT IN FUNDS - continued
Comparatives for movement in funds
| Unrestricted funds General fund Restricted funds Thalidomide Society Oral History Support for Srey Hang Srey Hang & Beyond HLF TOTAL FUNDS |
At 1.11.20 £ 514,450 3,511 1,341 4,553 27,642 37,047 551,497 |
Net movement in funds £ 83,642 249 - 2 (14,213) (13,962) 69,680 |
At 31.10.21 £ 598,092 3,760 1,341 4,555 13,429 |
|---|---|---|---|
| 23,085 | |||
| 621,177 |
Comparative net movement in funds, included in the above are as follows:
| Unrestricted funds General fund Restricted funds Thalidomide Society Oral History Srey Hang & Beyond HLF TOTAL FUNDS |
Incoming resources £ 19,863 2,501 2 10 2,513 22,376 |
Resources expended £ (43,342) (2,252) - (14,223) (16,475) (59,817) |
Gains and Movemen losses in funds £ £ 107,121 83,642 - 249 - 2 - (14,213) - (13,962) 107,121 69,680 |
Gains and Movemen losses in funds £ £ 107,121 83,642 - 249 - 2 - (14,213) - (13,962) 107,121 69,680 |
|---|---|---|---|---|
| (13,962) | ||||
| 69,680 |
A current year 12 months and prior year 12 months combined position is as follows:
| Unrestricted funds General fund Restricted funds Thalidomide Society Oral History Support for Srey Hang Srey Hang & Beyond HLF TOTAL FUNDS |
At 1.11.20 £ 514,450 3,511 1,341 4,553 27,642 37,047 551,497 |
Net movement in funds £ 14,969 7,387 (1,341) 3 (21,305) (15,256) (287) |
At 31.10.22 £ 529,419 10,898 - 4,556 6,337 |
|---|---|---|---|
| 21,791 | |||
| 551,210 |
continued...
Page 12
The Thalidomide Society
Notes to the Financial Statements - continued for the Year Ended 31 October 2022
11. MOVEMENT IN FUNDS - continued
A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:
| Unrestricted funds General fund Restricted funds Thalidomide Society Oral History Support for Srey Hang Srey Hang & Beyond HLF TOTAL FUNDS |
Incoming resources £ 102,748 10,047 - 4 14 10,065 112,813 |
Resources expended £ (167,358) (2,660) (1,341) (1) (21,319) (25,321) (192,679) |
Gains and Movement losses in funds £ £ 79,579 14,969 - 7,387 - (1,341) - 3 - (21,305) - (15,256) 79,579 (287) |
|---|---|---|---|
12. RELATED PARTY DISCLOSURES
There were no related party transactions for the year ended 31 October 2022.
Page 13
The Thalidomide Society
Detailed Statement of Financial Activities for the Year Ended 31 October 2022
| Detailed Statement of Financial Activities for the Year Ended 31 October 2022 |
||
|---|---|---|
| 31.10.22 | 31.10.21 | |
| £ | £ | |
| INCOME AND ENDOWMENTS | ||
| Donations and legacies | ||
| Donations | 42,587 | 1,585 |
| Lottery income | 1,545 | 1,705 |
| 44,132 | 3,290 | |
| Other trading activities | ||
| Merchandise income | 1,073 | - |
| Investment income | ||
| Investment income | 22,125 | 19,086 |
| Other income | ||
| Delgate fees | 23,107 | - |
| Total incoming resources | 90,437 | 22,376 |
| EXPENDITURE | ||
| Charitable activities | ||
| Grants to institutions | 1,342 | - |
| Support costs | ||
| Human resources | ||
| Wages | 31,817 | 27,607 |
| Social security | (323) | 3,922 |
| Pensions | 1,516 | 1,144 |
| Travel and subsistence costs | 3,778 | 2,564 |
| 36,788 | 35,237 | |
| Other | ||
| Insurance | 254 | 254 |
| Telephone and communications | 3,204 | 4,376 |
| Postage and stationery | 193 | 946 |
| Computer and IT expenses | 2,601 | 1,122 |
| Training seminars & workshops | 84,492 | 11,092 |
| Oral history interview costs | - | 3,090 |
| Memberships and subscriptions | - | 80 |
| Repairs and renewals | 179 | - |
| Investment fees | 1,017 | 998 |
| Accountancy fees | 1,920 | 1,920 |
| Legal fees | 872 | 702 |
| 94,732 | 24,580 | |
| Total resources expended | 132,862 | 59,817 |
| Net expenditure before gains and losses | (42,425) | (37,441) |
This page does not form part of the statutory financial statements
Page 14
The Thalidomide Society
| Detailed Statement of Financial Activities | ||
|---|---|---|
| for the Year Ended 31 October 2022 | ||
| 31.10.22 | 31.10.21 | |
| £ | £ | |
| Realised recognised gains and losses | ||
| Realised gains/(losses) on fixed asset investments | (27,542) | 107,121 |
| Net (expenditure)/income | (69,967) | 69,680 |
This page does not form part of the statutory financial statements
Page 15